Protalix BioTherapeutics (PLX) - מזומנים למניה

Protalix BioTherapeutics (PLX) revenues rely on a single drug for Fabry disease, creating a single-product risk. The cash per share metric provided by GURU.Markets shows a value of 0.59. The company utilizes its unique ProCellEx platform for low-cost protein synthesis in plants, while royalties from Elfabrio ensure a steady stream of high-margin free cash flow.
פילוחים אנליטיים של חברת Protalix BioTherapeutics (PLX)

This metric reflects the share of net liquid assets per common share, allowing for an assessment of the security's intrinsic value and the issuer's financial strength. By analyzing the cash per share trend, an investor can compare the rate of capital burn with the development of the unique plant-based platform of Protalix BioTherapeutics (PLX) within high-yield rare disease therapy niches.